RE: BBC news item this morning13 Nov 2022 17:31
Avacta’s proprietary pre|CISIONTM targeted chemotherapy platform, releases active drug in the tumour, thereby reducing systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta took its first pre|CISIONTM drug candidate AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic in summer 2021. The Company anticipates the results of this phase 1 study which will demonstrate safety and mechanism of action late in 2022 which will pave the way for further clinical development of AVA6000 and other pre|CISIONTM targeted chemotherapies.